A Prospective Observational Study - Comparing Levonorgestrel Intrauterine System and Other Treatment Modalities for Abnormal Uterine Bleeding in Terms of Bleeding Control, Safety, and Long-Term Outcomes | [Journal of Neonatal Surgery • 2024]

Author(s):

1. Rathna A.: Department of Obstetrics and Gynaecology, Saveetha Medical College and Hospital, Saveetha Nagar, Thandalam, Chennai - 602105, Tamil Nadu, India

2. Nidhi Sharma: Associate Professor, Department of Obstetrics and Gynaecology, Saveetha Medical College and Hospital,Saveetha Nagar, Thandalam, Chennai - 602105, Tamil Nadu,India

3. Evangeline Christable: Department of Obstetrics and Gynaecology, Saveetha Medical College and Hospital,Saveetha Nagar, Thandalam, Chennai - 602105, Tamil Nadu,India

Abstract:

Background: Abnormal uterine bleeding (AUB) affects 10-35% of reproductive-aged women, significantly impacting quality of life. The levonorgestrel-releasing intrauterine system (LNG-IUS) has emerged as a potential first-line treatment, though optimal patient selection criteria remain debated. Methods: In this prospective observational study, 132 women with AUB received LNG-IUS insertion and were followed for 12 months. Primary outcomes included menstrual blood loss (PBAC score) and hemoglobin changes. Secondary outcomes assessed satisfaction (Likert scale), discontinuation rates, and surgical intervention avoidance. Results: Participants demonstrated a 75.7% PBAC score reduction (p<0.001) and 2.2 g/dL hemoglobin increase (p<0.001). Patient satisfaction reached 88.7%, with only 9.6% discontinuation (primarily due to spotting). Hysterectomy was avoided in 85.5% of cases. Subgroup analysis revealed superior outcomes for ovulatory dysfunction (PBAC reduction: 82%) versus adenomyosis (68%). Prolonged spotting (38.7%) was the most common adverse effect, typically resolving by 6 months. Conclusions: LNG-IUS significantly improves AUB symptoms and reduces surgical needs, particularly in ovulatory dysfunction and small fibroids. While adenomyosis patients show slightly diminished response, most achieve meaningful clinical benefit. These findings support LNG-IUS as a first-line AUB therapy, emphasizing the importance of patient selection and anticipatory counseling regarding transient spotting.

Page(s): 324-333

DOI: DOI not available

Published: Journal: Journal of Neonatal Surgery, Volume: 13, Issue: 0, Year: 2024

Keywords:

menorrhagia , Abnormal uterine bleeding , hysterectomy prevention , medical therapy , LNGIUS

References:

[1] Lethaby A.,Hussain M.,Rishworth J. R.,Rees M. C. .2015 .Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database of Systematic Reviews, (4), CD002126. , : .

[2] Critchley H. O.,Wang H.,Kelly R. W.,Gebbie A. E.,Glasier A. F. .1998 .Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Human Reproduction, 13(5) : 1210-1217.

[3] Gupta J.,Kai J.,Middleton L.,Pattison H.,Gray R.,Daniels J. .2013 .Levonorgestrel intrauterine system versus medical therapy for menorrhagia. New England Journal of Medicine, 368(2) : 128-137.

[4] Osuga Y.,Hayashi K.,Kanda S. .2017 .Management of adenomyosis in women desiring fertility -An evidence-based approach. Reproductive Medicine and Biology, 16(3) : 214-221.

[5] Kaunitz A. M.,Bissonnette F.,Monteiro I.,Lukkari-Lax E.,Muysers C.,Jensen J. T. .2010 .Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: A randomized controlled trial. Obstetrics & Gynecology, 116(3) : 625-632.

[6] Lete I.,Obispo C.,Izquierdo A. .2008 .The levonorgestrel intrauterine system (Mirena®) for treatment of idiopathic menorrhagia: Assessment of quality of life and satisfaction. European Journal of Contraception and Reproductive Health Care, 13(3) : 231-237.

[7] Madden T.,Proehl S.,Allsworth J. E.,Peipert J. F. .2011 .Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: A randomized controlled trial. American Journal of Obstetrics and Gynecology, 10(2) : e1-129.

[8] Matteson K. A.,Rahn D. D.,Wheeler T. L.,II T. L. .2013 .Nonsurgical management of heavy menstrual bleeding: A systematic review. Obstetrics & Gynecology, 121(3) : 632-643.

[9] Hurskainen R.,Teperi J.,Rissanen P. .2004 .Clinical outcomes and costs with the levonorgestrelreleasing intrauterine system or hysterectomy for treatment of menorrhagia: Randomized trial 5-year followup. JAMA, 291(12) : 1456-1463.

[10] You J. H.,Sahota D. S.,MoYuen P. .2006 .A cost-utility analysis of hysterectomy, endometrial resection and ablation, and medical therapy for menorrhagia. Human Reproduction, 21(7) : 1878-1883.

[11] Bednarek P. H.,Jensen J. T. .2010 .Safety, efficacy and patient acceptability of the contraceptive and non - contraceptive uses of the LNG-IUS. International Journal of Women's Health, 1 : 45-58.

Citations

Downloads

Views